This module uses fundamental data of Briacell Therapeutics to approximate its Piotroski F score. Briacell Therapeutics F Score is determined by combining nine binary scores representing 3 distinct fundamental categories of Briacell Therapeutics Corp. These three categories are profitability, efficiency, and funding. Some research analysts and sophisticated value traders use Piotroski F Score to find opportunities outside of the conventional market and financial statement analysis.They believe that some of the new information about Briacell Therapeutics financial position does not get reflected in the current market share price suggesting a possibility of arbitrage. Check out Briacell Therapeutics Altman Z Score, Briacell Therapeutics Correlation, Briacell Therapeutics Valuation, as well as analyze Briacell Therapeutics Alpha and Beta and Briacell Therapeutics Hype Analysis.
Briacell
Piotroski F Score
Market Cap
Enterprise Value
Ptb Ratio
Book Value Per Share
Free Cash Flow Yield
Invested Capital
Operating Cash Flow Per Share
Average Payables
Capex To Depreciation
Pb Ratio
Free Cash Flow Per Share
Inventory Turnover
Net Income Per Share
Days Of Inventory On Hand
Average Inventory
Cash Per Share
Pocfratio
Interest Coverage
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Tangible Asset Value
Ev To Operating Cash Flow
Pe Ratio
Ev To Free Cash Flow
Intangibles To Total Assets
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Graham Number
Shareholders Equity Per Share
Debt To Equity
Capex Per Share
Graham Net Net
Average Receivables
Interest Debt Per Share
Debt To Assets
Enterprise Value Over E B I T D A
Roic
Payables Turnover
Roe
Return On Tangible Assets
Earnings Yield
Short Term Coverage Ratios
Price Earnings Ratio
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Ebt Per Ebit
Effective Tax Rate
Company Equity Multiplier
Total Debt To Capitalization
Debt Equity Ratio
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Net Income Per E B T
Cash Ratio
Days Of Inventory Outstanding
Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios
Price To Book Ratio
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Debt Ratio
Cash Flow To Debt Ratio
Price Fair Value
Return On Capital Employed
Return On Assets
Return On Equity
Change In Cash
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Other Non Cash Items
Capital Expenditures
Total Cash From Operating Activities
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Other Cashflows From Financing Activities
Sale Purchase Of Stock
Stock Based Compensation
Depreciation
Change To Account Receivables
Investments
Net Borrowings
Total Cashflows From Investing Activities
Change To Operating Activities
Change To Netincome
Change To Liabilities
Issuance Of Capital Stock
Change To Inventory
Total Assets
Total Current Liabilities
Total Stockholder Equity
Net Debt
Retained Earnings
Accounts Payable
Cash
Non Current Assets Total
Non Currrent Assets Other
Cash And Short Term Investments
Common Stock Shares Outstanding
Liabilities And Stockholders Equity
Non Current Liabilities Total
Other Stockholder Equity
Total Liab
Total Current Assets
Net Receivables
Other Current Liab
Property Plant And Equipment Net
Inventory
Other Current Assets
Property Plant And Equipment Gross
Accumulated Other Comprehensive Income
Short Term Investments
Intangible Assets
Net Tangible Assets
Current Deferred Revenue
Net Invested Capital
Net Working Capital
Common Stock
Short Long Term Debt Total
Common Stock Total Equity
Short Long Term Debt
Capital Stock
Short Term Debt
Non Current Liabilities Other
Other Liab
Depreciation And Amortization
Interest Expense
Other Operating Expenses
Operating Income
Ebit
Ebitda
Total Operating Expenses
Income Tax Expense
Selling General Administrative
Income Before Tax
Total Other Income Expense Net
Research Development
Net Interest Income
Interest Income
Net Income From Continuing Ops
Reconciled Depreciation
Net Income Applicable To Common Shares
Gross Profit
Cost Of Revenue
Probability Of Bankruptcy
Total Debt To Capitalization is likely to rise to 0.0005 in 2024, whereas Net Debt is likely to drop (905.2 K) in 2024. At this time, Briacell Therapeutics' ROE is fairly stable compared to the past year.
At this time, it appears that Briacell Therapeutics' Piotroski F Score is Frail. Although some professional money managers and academia have recently criticized Piotroski F-Score model, we still consider it an effective method of predicting the state of the financial strength of any organization that is not predisposed to accounting gimmicks and manipulations. Using this score on the criteria to originate an efficient long-term portfolio can help investors filter out the purely speculative stocks or equities playing fundamental games by manipulating their earnings..
The critical factor to consider when applying the Piotroski F Score to Briacell Therapeutics is to make sure Briacell is not a subject of accounting manipulations and runs a healthy internal audit department. So, if Briacell Therapeutics' auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back. Below are the main accounts that are used in the Piotroski F Score model. By analyzing the historical trends of the mains drivers, investors can determine if Briacell Therapeutics' financial numbers are properly reported.
One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to project the various growth rates. Understanding the correlation between Briacell Therapeutics' different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Briacell Therapeutics in a much-optimized way.
F-Score is one of many stock grading techniques developed by Joseph Piotroski, a professor of accounting at the Stanford University Graduate School of Business. It was published in 2002 under the paper titled Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers. Piotroski F Score is based on binary analysis strategy in which stocks are given one point for passing 9 very simple fundamental tests, and zero point otherwise. According to Mr. Piotroski's analysis, his F-Score binary model can help to predict the performance of low price-to-book stocks.
Book Value Per Share
(0.26)
At this time, Briacell Therapeutics' Book Value Per Share is fairly stable compared to the past year.
Briacell Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Briacell Therapeutics from analyzing Briacell Therapeutics' financial statements. These drivers represent accounts that assess Briacell Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Briacell Therapeutics' important valuation drivers and their relationship over time.
The Macroaxis Fundamental Analysis modules help investors analyze Briacell Therapeutics Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Briacell Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Briacell Therapeutics Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When running Briacell Therapeutics' price analysis, check to measure Briacell Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Briacell Therapeutics is operating at the current time. Most of Briacell Therapeutics' value examination focuses on studying past and present price action to predict the probability of Briacell Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Briacell Therapeutics' price. Additionally, you may evaluate how the addition of Briacell Therapeutics to your portfolios can decrease your overall portfolio volatility.